What you need to know on donanemab
On May 3, American drug company Eli Lilly and Company released some results from a Phase 3 trial of donanemab, a drug that aims to target Alzheimer’s disease.

Important notice: Mail will be disrupted by the Canada Post strike. Please contact our administrative office to make arrangements to have correspondence sent to you by email. Phone: 1-866-950-5465 or E-mail: help@alzheimer.ab.ca
On May 3, American drug company Eli Lilly and Company released some results from a Phase 3 trial of donanemab, a drug that aims to target Alzheimer’s disease.